Literature DB >> 33795844

Unravelling the potential of angiogenic factors for the early prediction of preeclampsia.

Juilee S Deshpande1, Deepali P Sundrani1, Akriti S Sahay1, Sanjay A Gupte2, Sadhana R Joshi3.   

Abstract

Preeclampsia is a multisystem, multiorgan hypertensive disorder of pregnancy responsible for maternal and perinatal morbidity and mortality in low- and middle-income countries. The classic diagnostic features hold less specificity for preeclampsia and its associated adverse outcomes, suggesting a need for specific and reliable biomarkers for the early prediction of preeclampsia. The imbalance of pro- and antiangiogenic circulatory factors contributes to the pathophysiology of preeclampsia. Several studies have examined the profile of angiogenic factors in preeclampsia to search for a biomarker that will improve the diagnostic ability of preeclampsia and associated adverse outcomes. This may help in more efficient patient management and the reduction of associated health care costs. This article reviews the findings from previous studies published to date on angiogenic factors and suggests a need to apply a multivariable model from the beginning of pregnancy and continuing throughout gestation for the early and specific prediction of preeclampsia.

Entities:  

Keywords:  Placental growth factor (PlGF); Preeclampsia; Soluble endoglin (sEndoglin); Soluble fms-like tyrosine kinase-1 (sFlt-1); Vascular endothelial growth factor (VEGF); sFlt-1 to PlGF ratio

Mesh:

Substances:

Year:  2021        PMID: 33795844     DOI: 10.1038/s41440-021-00647-9

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  70 in total

1.  The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP.

Authors:  A L Tranquilli; G Dekker; L Magee; J Roberts; B M Sibai; W Steyn; G G Zeeman; M A Brown
Journal:  Pregnancy Hypertens       Date:  2014-02-15       Impact factor: 2.899

Review 2.  Diagnostic utility of angiogenic biomarkers in pregnant women with suspected preeclampsia: A health economics review.

Authors:  Dietmar Schlembach; Martin Hund; Cyrill Wolf; Manu Vatish
Journal:  Pregnancy Hypertens       Date:  2019-03-11       Impact factor: 2.899

Review 3.  The Use of Soluble FMS-like Tyrosine Kinase 1/Placental Growth Factor Ratio in the Clinical Management of Pre-eclampsia.

Authors:  Nalini Govender; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Afr J Reprod Health       Date:  2018-12

4.  Differential Expression of Placental Growth Factor, Transforming Growth Factor-β and Soluble Endoglin in Peripheral Mononuclear Cells in Preeclampsia.

Authors:  Zaima Ali; Zaima Ali; Saba Khaliq; Saima Zaki; Hafiz Usman Ahmad; Khalid Pervaiz Lone
Journal:  J Coll Physicians Surg Pak       Date:  2019-03       Impact factor: 0.711

Review 5.  Vascular endothelial growth factor and angiogenesis.

Authors:  Ann Hoeben; Bart Landuyt; Martin S Highley; Hans Wildiers; Allan T Van Oosterom; Ernst A De Bruijn
Journal:  Pharmacol Rev       Date:  2004-12       Impact factor: 25.468

Review 6.  Preeclampsia-eclampsia.

Authors:  Sanjay Gupte; Girija Wagh
Journal:  J Obstet Gynaecol India       Date:  2014-01-31

Review 7.  The role of angiogenic factors in the management of preeclampsia.

Authors:  Emma J Flint; A Sofia Cerdeira; Christopher W Redman; Manu Vatish
Journal:  Acta Obstet Gynecol Scand       Date:  2019-02-22       Impact factor: 3.636

Review 8.  Angiogenic factors and preeclampsia.

Authors:  Sharon E Maynard; S Ananth Karumanchi
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

Review 9.  The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.

Authors:  David I R Holmes; Ian Zachary
Journal:  Genome Biol       Date:  2005-02-01       Impact factor: 13.583

Review 10.  Recent advances in the diagnosis and management of pre-eclampsia.

Authors:  Kate Duhig; Brooke Vandermolen; Andrew Shennan
Journal:  F1000Res       Date:  2018-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.